NASDAQ:ANAB - AnaptysBio Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$73.05 +0.30 (+0.41 %)
(As of 01/21/2019 06:00 AM ET)
Previous Close$73.05
Today's Range$68.83 - $73.71
52-Week Range$54.26 - $134.00
Volume186,979 shs
Average Volume231,195 shs
Market Capitalization$1.95 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.98
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.

Receive ANAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ANAB
CUSIPN/A
Phone858-362-6295

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10 million
Book Value$13.09 per share

Profitability

Net Income$-30,070,000.00

Miscellaneous

Employees60
Market Cap$1.95 billion
OptionableOptionable

AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How were AnaptysBio's earnings last quarter?

AnaptysBio Inc (NASDAQ:ANAB) announced its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.05. The biotechnology company earned $5 million during the quarter. View AnaptysBio's Earnings History.

When is AnaptysBio's next earnings date?

AnaptysBio is scheduled to release their next quarterly earnings announcement on Monday, March 4th 2019. View Earnings Estimates for AnaptysBio.

What price target have analysts set for ANAB?

10 Wall Street analysts have issued 12 month price targets for AnaptysBio's stock. Their predictions range from $84.00 to $153.00. On average, they expect AnaptysBio's share price to reach $127.20 in the next twelve months. This suggests a possible upside of 74.1% from the stock's current price. View Analyst Price Targets for AnaptysBio.

What is the consensus analysts' recommendation for AnaptysBio?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AnaptysBio.

What are Wall Street analysts saying about AnaptysBio stock?

Here are some recent quotes from research analysts about AnaptysBio stock:
  • 1. According to Zacks Investment Research, "AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. " (1/16/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our 12-month price target of $126/share is based on an equally weighted composite of (a) $90.5/share, as a 35x multiple of taxed and diluted FY32 GAAP EPS of $27.66 discounted back to and (b) an NPV of $161/share (discount rate 12.0%, growth rate 2.0%). The assumptions are in-line with the expected PE multiple and discount rate of an early development-stage biotechnology company." (12/20/2018)
  • 3. Cantor Fitzgerald analysts commented, ". $140 price target. We think positive Dupixent phase 3 nasal polyp data from REGN (Neutral)/SNY (Not Covered) is an incremental positive for ANAB as it helps de-risk ANAB’s readout in this indication in 2H 2019. ANAB is also studying etokimab in chronic sinusitis with nasal polyps (CSwNP) and is guiding for phase 2 data in 2H19 (n=100, placebo controlled study). Because of the similarities in Dupixent and etokimab mechanisms of actions, we believe this should increase the likelihood of etokimab’s success in this study." (10/16/2018)

Has AnaptysBio been receiving favorable news coverage?

Media stories about ANAB stock have trended somewhat negative recently, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AnaptysBio earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.

Who are some of AnaptysBio's key competitors?

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the folowing people:
  • Mr. Hamza Suria, Pres, CEO & Director (Age 43)
  • Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 44)
  • Prof. Marco Londei, Chief Medical Officer (Age 62)
  • Dr. Margaret Marino Ph.D., VP of Project Management
  • Mr. Peter Smith, VP of Commercial Strategy

When did AnaptysBio IPO?

(ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

How do I buy shares of AnaptysBio?

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $73.05.

How big of a company is AnaptysBio?

AnaptysBio has a market capitalization of $1.95 billion and generates $10 million in revenue each year. The biotechnology company earns $-30,070,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. AnaptysBio employs 60 workers across the globe.

What is AnaptysBio's official website?

The official website for AnaptysBio is http://www.anaptysbio.com.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]


MarketBeat Community Rating for AnaptysBio (NASDAQ ANAB)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  242 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  411
MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe ANAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Featured Article: Trading Strategy

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel